MIAMI, FL--(MARKET WIRE)--Sep 25, 2007 -- DOR BioPharma, Inc. (OTC BB:DORB.OB - News) ("DOR" or the "Company") announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance of patent claims based on U.S. Patent Application #09/433,418 entitled "Topical Azathioprine for the Treatment of Oral Autoimmune Diseases." Concurrently, the patent has also been issued by the European Patent Office with the serial number EP 1 212 063 B1. This patent family specifically includes claims for treatment and prevention of oral graft versus host disease (GVHD) with locally or topically applied azathioprine, a potent immunosuppressive drug. Oral GVHD can occur in up to 70% of patients who have undergone bone marrow/stem cell transplantation despite treatment with other immunosuppressive drugs such as prednisone, methotrexate, tacrolimus, and cyclosporine.
